Comparison of Pulmonary Involvement Between Patients Expressing Anti-PL-7 and Anti-Jo-1 Antibodies

Tomonaga, M; Sakamoto, Noriho; Ishimatsu, Yuji; Kakugawa, Tomoyuki; Harada, Tatsuhiko; Nakashima, Shota; Hara, Atsuko; Hara, Shintaro; Horai, Yoshihiro; Kawakami, Atsushi; Mukae, Hiroshi; Kohno, Shigeru

doi:10.1007/s00408-014-9665-7

Cited by 17 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 4 ] However, ILD in AS may be indistinguishable from that of IIP in patients with subclinical or sine myositis. Similar to earlier reports,[ 4 23 ] NSIP pattern was the most common pattern of ILD in our patients with AS. Also, the mean age of our patients was 43.8 years, which is less than that in IIPs.…”

Section: Discussionsupporting

confidence: 92%

Antisynthetase syndrome: An under-recognized cause of interstitial lung disease

et al. 2016

View full text Add to dashboard Cite

Background:Antisynthetase syndrome (AS) is an uncommon and under-recognised connective tissue disease characterized by the presence of antibodies to anti-aminoacyl t-RNA synthetase along with features of interstitial lung disease (ILD), myositis and arthritis. The aim of the current study is to describe our experience with management of AS.Materials and Methods:This was a 2-year (2013-2014) retrospective analysis of patients diagnosed with anti-Jo-1-related AS. The presence of anti-Jo-1 antibody was tested by the immunoblot assay. All patients underwent high-resolution computed tomography of the chest, transthoracic echocardiography and evaluation for inflammatory myositis. Transbronchial lung biopsies and muscle biopsies were obtained when clinically indicated.Results:Nine patients (mean age: 43.8 years) were diagnosed with anti-Jo-1-related AS. The median duration of symptoms before diagnosis of AS was 6 months. All patients were negative for antinuclear antibodies by indirect immunofluorescence. The prevalence of ILD, myositis and arthritis at presentation was 100%, 77.8% and 55.6%, respectively. The most common ILD pattern was non-specific interstitial pneumonia (n = 6) followed by organizing pneumonia (n = 2) and usual interstitial pneumonia (n = 1). ILD was the sole manifestation in two patients and was subclinical in two patients. Six patients had pleuropericardial effusions, three patients had pulmonary artery hypertension and two patients had venous thromboembolism. Eight of the nine patients improved after treatment with steroids and other immunosuppressants.Conclusion:Antisynthetase syndrome is an important and a treatable cause of ILD. Strong clinical suspicion is needed to achieve an early diagnosis.

show abstract

Section: Discussionsupporting

confidence: 92%

Antisynthetase syndrome: An under-recognized cause of interstitial lung disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…These differences were not significant, and we speculate that the 2 main reasons for this were the shorter disease duration of the non-Jo1 subset and the low number of non-Jo1 cases. Overall, it appears that our PFT and CT data are consistent with antisynthetase syndrome subset studies with shorter time of followup 15,18 , and also with the recent, small-sized, longterm followup study from Tomonaga, et al in Japan 41 .…”

Section: Rheumatologysupporting

confidence: 89%

Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study

Andersson

Aaløkken²,

Günther³

et al. 2016

J Rheumatol

View full text Add to dashboard Cite

To our knowledge, this study is the first to demonstrate a highly significant difference in PFT between patients with antisynthetase syndrome with 6 years of followup and healthy controls. DLCO displayed the highest difference with mean 53% lower value in the patients. FVC and DLCO correlated significantly with ILD extent, indicating these variables as appropriate outcome measures in antisynthetase syndrome-associated ILD.

show abstract

“…Also, Gonzalez-Perez and colleagues observed no differences between anti-synthetase patients with and without anti-Jo-1 autoantibody in 118 patients with ILD and positivity to one anti-synthetase antibody in terms of lung function during a follow up of 749 days [10]. No differences were observed in another smaller study analyzing 21 patients [24].…”

Section: Discussionmentioning

confidence: 93%

Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis

Dei

Rebora

Catalano

et al. 2020

JCM

View full text Add to dashboard Cite

Antisynthetase syndrome (ASSD) is a rare autoimmune disease characterized by serologic positivity for antisynthetase antibodies. Anti-Jo1 is the most frequent, followed by anti PL-7, anti PL-12, anti EJ, and anti OJ antibodies. The lung is the most frequently affected organ, usually manifesting with an interstitial lung disease (ILD), which is considered the main determinant of prognosis. Some evidences suggest that non-anti-Jo-1 antibodies may be associated with more severe lung involvement and possibly with poorer outcomes, while other authors do not highlight differences between anti-Jo1 and other antisynthetase antibodies. In a multicenter, retrospective, “real life” study, we compared lung function tests (LFTs) progression in patients with ILD associated with anti-Jo1 and non-anti-Jo1 anti-synthetase antibodies to assess differences in lung function decline between these two groups. Therefore, we analyzed a population of 57 patients (56% anti-Jo1 positive), referred to the outpatient Clinic of four referral Centers in Italy (Modena, Monza, Siena, and Trieste) from 2008 to 2019, with a median follow-up of 36 months. At diagnosis, patients showed a mild ventilatory impairment and experienced an improvement of respiratory function during treatment. We did not observe statistically significant differences in LFTs at baseline or during follow-up between the two groups. Moreover, there were no differences in demographic data, respiratory symptoms onset (acute vs. chronic), extrapulmonary involvement, treatment (steroid and/or another immunosuppressant), or oxygen supplementation. Our study highlights the absence of differences in pulmonary functional progression between patients positive to anti-Jo-1 vs. non anti-Jo-1 antibodies, suggesting that the type of autoantibody detected in the framework of ASSD does not affect lung function decline.

show abstract

Comparison of Pulmonary Involvement Between Patients Expressing Anti-PL-7 and Anti-Jo-1 Antibodies

Cited by 17 publications

References 18 publications

Antisynthetase syndrome: An under-recognized cause of interstitial lung disease

Antisynthetase syndrome: An under-recognized cause of interstitial lung disease

Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study

Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis

Contact Info

Product

Resources

About